Enterome gets IBD candidates from Vertex
Executive Summary
Vertex Pharmaceuticals Inc. licensed Enterome Bioscience SA exclusive worldwide rights to develop and commercialize small-molecule FimH antagonists for treating inflammatory bowel diseases (IBD) including Crohn's.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice